Related Experiment Video
Updated: Jan 6, 2026
Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
Published on: July 8, 2011
Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy
Mridula Prakash1, Cedric David Cortez1,2, Akshaya Jayaraman1
1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Abstract:
Dendritic cells (DCs) play a crucial role in the coordination of immune responses and have emerged as a potential target for cancer immunotherapy. However, existing DC-based immunotherapies face several clinical challenges, including suboptimal manipulation strategies, poor cross-presentation, and impaired migration. Besides, the complex tumor milieu drives DCs towards a tolerogenic state, leading to immune evasion and cancer progression. Hence, innovative engineering strategies emerging from a thorough understanding of the genetic and molecular aspects of the factors driving DCs to an immune-compromised status will benefit cancer immunotherapy. Taking advantage of the multiplexing potential of gene editing methods such as CRISPR/Cas9 and viral vectors will ensure multiple genome modifications in DCs that can result in higher migration, cross-presentation, and immune-activating cytokine production in a single manipulation step. Such precise DC modifications with high accuracy require the involvement of nanocarrier formulations with high surface functionalization and targeting potential. In this regard, our review provides a comprehensive summary of critical tumor-induced dysfunctions in DCs and promising genome engineering strategies, highlighting nanocarrier-based approaches to mitigate these challenges.
Insights
Engineered dendritic cells (DCs) show promise for cancer immunotherapy by overcoming challenges like poor migration and immune evasion. Gene editing and nanocarrier strategies offer precise DC modifications for enhanced anti-tumor immunity.
Area of Science:
- Immunology
- Cancer Research
- Biotechnology
Background:
- Dendritic cells (DCs) are key regulators of immune responses and a target for cancer immunotherapy.
- Current DC-based therapies face challenges including poor manipulation, cross-presentation, and migration, exacerbated by the tumor microenvironment's tolerogenic effects.
- Tumor-induced dysfunction compromises DC anti-cancer activity, leading to immune evasion.
Purpose of the Study:
- To review tumor-induced dysfunctions in dendritic cells (DCs).
- To explore innovative genome engineering strategies for enhancing DC function in cancer immunotherapy.
- To highlight nanocarrier-based approaches for precise DC modification.
Main Methods:
- Review of current literature on DC biology and cancer immunotherapy.
- Analysis of gene editing technologies (e.g., CRISPR/Cas9) and viral vectors for DC manipulation.
- Examination of nanocarrier formulations for targeted delivery and functionalization of DCs.
Main Results:
- Tumor microenvironment significantly impairs DC function, promoting immune tolerance.
- Multiplex genome editing offers a strategy to simultaneously enhance DC migration, cross-presentation, and cytokine production.
- Nanocarrier systems provide precise surface functionalization and targeting for engineered DCs.
Conclusions:
- Understanding tumor-induced DC dysfunction is critical for developing effective cancer immunotherapies.
- Genome engineering, particularly multiplex approaches, holds significant potential for reprogramming DCs.
- Nanocarrier-mediated delivery is essential for achieving targeted and accurate DC modifications, paving the way for advanced DC-based cancer treatments.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Microorganisms in Medicine and Therapeutics